Treating multiple sclerosis (MS) with monoclonal antibodies ... Following this, the newer anti-CD20 mAbs ocrelizumab and ofatumumab, which are currently being tested in Phase II for MS, are ...

Ocrelizumab showed higher adherence and ... in pivotal clinical trials among patients with different types of multiple sclerosis (MS). The analysis of 30 studies on real-world use of the ...

Anti-CD20 agents: B lymphocyte depletion: Rituximab no longer being pursued for multiple sclerosis (MS) indication. Ocrelizumab Phase II with positive results, several Phase III underway.

Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

According to the MS Society, certain medications like ocrelizumab (Ocrevus) can slow the progression of the disease in primary progressive multiple sclerosis, and syponimod (Mayzent) can help with ...

A Phase 2 clinical trial testing obexelimab in adults with relapsing types of multiple sclerosis is now recruiting ...

Less frequent Ocrevus infusions are just as effective in controlling MS, but may help limit the risk of side effects, per a ...

Ocrelizumab is an intravenous (IV) infusion medication used to treat certain types of multiple sclerosis (MS) and clinically isolated syndrome. Interaction result: Taking Tecfidera with ...

Multiple sclerosis (MS) is a disease that looks different ... Nearly half of them have chosen to be on ocrelizumab (brand name Ocrevus), a monoclonal antibody infusion that's given twice a year.